MedTrace Logo

Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

NCT05483257 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 226

Last updated 2022-08-02

No results posted yet for this study

Summary

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

Conditions

  • Pancreatic Cancer Resectable

Interventions

DEVICE

Multigene panel for next-generation sequencing

HLA-I genotyping based on next-generation sequencing for prognosis evaluation

Sponsors & Collaborators

  • GeneCast Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • BAIYONG SHEN

    lead OTHER

Eligibility

Min Age
34 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-14
Primary Completion
2020-08-03
Completion
2021-09-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05483257 on ClinicalTrials.gov